Today we’re getting under the hood of Linda Greub a mother, daughter, sister, friend, women’s advocate, and the co-founder and managing partner of Avestria Ventures.
For over 30+ years, Linda has invested in public and private life science companies as an institutional investor, a corporate M&A executive, a hedge fund analyst, and a private venture investor. She's held roles at companies such as Essex Investment Management, Bank of America Securities, Novartis Diagnostics, Applied Biosystems (sold to Life Technologies Corp.) as well as at venture-backed life science companies such as VitaPath Genetics, Singulex, Raindance Technologies (sold to Bio-Rad), and Linkage Biosciences (sold to Thermo Fisher).
In 2010, Linda started angel investing with two of her Harvard Business School classmates, focusing on female-founded startups. One of the companies in their portfolio was nVision, a female-founded, women’s health-focused startup that was acquired by Boston Scientific in 2018 for up to $275 million. The trouble that nVision had fundraising from the male-dominant venture capital industry - and its subsequent success nonetheless - led Linda and one of her fellow angel investors to found Avestria Ventures in 2019 to focus exclusively on early-stage women’s health and female-led life science ventures.
Linda’s areas of expertise include finance, operations, and mergers as well as the life sciences, specifically, diagnostics, genomics, healthcare services, and life science tools.
Linda received her B.A. from Yale and her MBA from Harvard Business School.
If you haven’t already, please give us a quick review and rating on Apple podcasts and Spotify and don’t forget you can follow us FaceBook, Instagram, Twitter and YouTube.